Development of improved therapeutic mesothelin-based vaccines for pancreatic cancer.
Pancreatic cancer is the 5th leading cause of cancer deaths, and there are no effective treatments. We developed a poxvirus platform vaccine with improved immunogenicity and inserted the mesothelin gene to create an anti-mesothelin cancer vaccine. Mesothelin expression is mostly restricted to tumors...
Main Authors: | Michael White, Andrew Freistaedter, Gwendolyn J B Jones, Emmanuel Zervos, Rachel L Roper |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2018-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5825036?pdf=render |
Similar Items
-
Low serum mesothelin in pancreatic cancer patients results from retention of shed mesothelin in the tumor microenvironment
by: Xianyu Zhang, et al.
Published: (2022-07-01) -
Methylation-associated partial down-regulation of mesothelin causes resistance to anti-mesothelin immunotoxins in a pancreatic cancer cell line.
by: Kevin Hollevoet, et al.
Published: (2015-01-01) -
From Malignant Progression to Therapeutic Targeting: Current Insights of Mesothelin in Pancreatic Ductal Adenocarcinoma
by: Christopher Montemagno, et al.
Published: (2020-06-01) -
Targeting mesothelin in cancer
by: Cem Elbi
Published: (2023-12-01) -
Mesothelin blockage by Amatuximab suppresses cell invasiveness, enhances gemcitabine sensitivity and regulates cancer cell stemness in mesothelin-positive pancreatic cancer cells
by: Fumihiko Matsuzawa, et al.
Published: (2021-02-01)